The department of Neurology offers treatment options to patients through clinical trials and research studies in the areas of pharmaceuticals, biologics and medical devices. Examples of currently enrolling trials include:
An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF with Adjuvant Temozolomide in Patients with Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma (ACT IV Study)
Dr. Jennifer Connelly, a neuro-oncologist, is the local principle investigator for this clinical trial in which patients are randomly selected to receive the vaccine called Rindopepimut, in addition to standard therapy. Rindopepimut targets a mutated protein known as EGFRvIII that is present in the tumor cells of about 30 percent of patients with Glioblastoma multiforme. Rindopepimut stimulates the immune system to recognize the target protein and kill any cells that contain it. Normal cells are left untouched, so side effects are minimal. All participants will first get standard therapy and then receive either the vaccine or a control. By adding the vaccine treatment to standard therapy, researchers hope to prove that the vaccine shrinks or prevents the tumors from growing, while increasing average survival.
Memory Loss and Functional MRI (fMRI) Study
The purpose of the fMRI study is to compare the brain activity of healthy volunteers to that of people with memory loss. The ultimate goal is to develop an early diagnostic tool for Alzheimer’s disease. Participants will have one visit for brief memory testing, neurological examination, buccal (cheek) swab for genetic testing, and an MRI. The visit will take approximately 2½ hours. Participants should be 50 years of age or older and have a clinical diagnosis of mild cognitive impairment, Alzheimer’s disease, or frontotemporal dementia (includes primary progressive aphasia). An honorarium and parking expenses will be paid. To obtain a study application or for further information, call Jennifer Jones at (414) 805-5232.
Brain Regions Involved in Speech Recognition
This study focuses on the brain’s function in the recognition of speech sounds and understanding of spoken language The goal of this study is to define the difference between the middle and posterior temporal region of the brain for speech and auditory perception. Einat Liebenthal, PhD, associate professor of neurology, is lead investigator for the grant.
Understanding the roles of these brain regions may lead to improvements in the treatment of speech perception disorders, in particular, dyslexia.
Delineating the brain areas involved in different aspects of processing speech is a key building block for developing a functional map of the cerebral cortex, where memory and language perception take place. Additionally, a map of the cerebral cortex is a valuable tool for surgical planning.